Teva Pharmaceutical Industries (NYSE:TEVA) VP Sells $3,311,622.24 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares of the company’s stock, valued at $1,387,653.12. This trade represents a 70.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA traded up $0.36 during midday trading on Thursday, reaching $30.16. 9,875,317 shares of the company’s stock traded hands, compared to its average volume of 11,815,374. The company has a fifty day simple moving average of $23.03 and a two-hundred day simple moving average of $19.44. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $30.20. The company has a market cap of $34.59 billion, a P/E ratio of 50.27, a PEG ratio of 1.53 and a beta of 0.67. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently made changes to their positions in TEVA. Steadtrust LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 58.1% in the 3rd quarter. Steadtrust LLC now owns 37,300 shares of the company’s stock worth $753,000 after acquiring an additional 13,700 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $1,392,000. CIBC Private Wealth Group LLC raised its position in Teva Pharmaceutical Industries by 15.5% in the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after purchasing an additional 540 shares during the period. CIBC Bancorp USA Inc. acquired a new position in Teva Pharmaceutical Industries during the third quarter worth $234,000. Finally, Centaurus Financial Inc. lifted its stake in Teva Pharmaceutical Industries by 25.2% during the third quarter. Centaurus Financial Inc. now owns 51,612 shares of the company’s stock worth $1,043,000 after purchasing an additional 10,384 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on TEVA shares. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Finally, Bank of America increased their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $30.25.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.